Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters
The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.
Bristol Myers Squibb's (BMY) cancer drug, izalontamab brengitecan (iza-bren), has shown promising results in a recent Phase 3 trial, doubling the progression-free survival (PFS) time for patients with non-small cell lung cancer (NSCLC) who had previously undergone treatment with an EGFR tyrosine kinase inhibitor (TKI). The trial, conducted by Sichuan Biokin Pharmaceutical, a Chinese company, demonstrated that iza-bren extended PFS to 11.1 months, compared to 5.7 months for patients receiving chemotherapy.
Despite positive data and a manageable safety profile, Bristol Myers Squibb's stock did not experience a significant increase, as the drug's performance was only evaluated in mainland China, which is not considered sufficient for FDA approval. Additionally, the trial's overall survival data remain immature, and competitors are also developing similar drugs targeting solid tumors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
